home > news > detailed info

Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand


Bangkok, Thailand and Weimar, Germany – September 2020: National Science and Technology Development Agency Thailand (NSTDA) is implementing the Government’s Thailand 4.0 initiative to promote strategic biotechnology growth at the country’s Eastern Economic Corridor of Innovation (EECi). One part of this new BIOPOLIS complex is the GMP Biorefinery Pilot Plant at EECi, for which German engineering company Glatt Ingenieurtechnik was selected to provide the engineering services. The contract between NSTDA and Glatt comprises the Conceptual and Basic Design phases for the GMP Biorefinery.
 Fig. (NSTDA©): BIOPOLIS plant complex with indication of GMP Biorefinery building within the complex

The main objective of the GMP Biorefinery Pilot Plant at EECi is to provide a “non-proprietary (generic) equipment” platform for private and public organizations, as well as local and international universities to scale-up and validate their laboratory prototypes and perform techno-economic feasibility studies before investing in specific production lines.

The Biorefinery platform will be designed in such a way that allows users to reconfigure the unit operation arrangement ("LEGO® box'' concept) and adjust the operating parameters to extreme values to optimize the process conditions (flexible process window for optimization) and customize or scale-up the equipment. Glatt Ingenieurtechnik in Germany will lead the engineering project and design the biotech process plant.

Eastern Economic Corridor of Innovation (EECi) aims to advance and transform existing industries, both within the EEC and in other parts of the Thailand, through innovative research and development and advanced laboratory scale technology development to actual industrial application. Innovative Agriculture and Biorefinery are among the target industries of EECi. Thailand has developed a basic infrastructure to support the growth of the Biorefinery industry. Thailand’s Government has approved the investment policy infrastructure at EECi as a central facility to advance targeted Biorefinery technologies to higher Technology Readiness Level (TRL).

National Science and Technology Development Agency Thailand (NSTDA) is a government agency established to promote the development of science and technology in Thailand. NSTDA has multiple cooperations worldwide with research institutes, innovate industry, university and many companies. NSTDA was established in December 1991 as an autonomous Government agency under the National Science and Technology Development Act 1991. NSTDA is affiliated to the Ministry of Higher Education, Science, Research and Innovation, with the Minister serving as the chairman of NSTDA Governing Board. NSTDA is entrusted with an important task to accelerate science, technology and innovation development in Thailand to respond to the need of the industry and enhance the country's competitiveness in the global economy, and as a result, making contribution to national economic and social development. NSTDA’s mission is to perform and support Research and Development, Design and Engineering, Technology Transfer, Science and Technology Human Resource Development and Infrastructure Development. This mission is implemented through working with partners from academic, government, private, and non-government sectors, both domestically and internationally.

Glatt Ingenieurtechnik GmbH plans and carries out international projects from the enlargement or modernization of existing production facilities to the construction of whole new factories. In doing so, the company combines professional engineering with sound technical know-how derived from patented process technologies it has developed itself, such as Glatt powder synthesis and fluidized and spouted bed methods for granulation and coating processes. The focus of the projects is on processes in the field of particle design and particle engineering for the development, optimization, functionalization and production of powder and bulk goods such as granulates and pellets for food, feed, chemicals and fine chemicals and processes for the manufacture of biotechnological and chemical active ingredients for sterile and non-sterile dosage forms of drugs.

Within the competence area of Process & Plant Engineering the company provides long year competences in biotechnological projects as well as in chemical synthesis engineering and has wide project experience in Asia, including Thailand, India, China, Vietnam, Bangladesh and further countries.

Glatt Ingenieurtechnik GmbH has its headquarters in Weimar. Affiliates are located in Wiesbaden and Dresden, Switzerland, Russia, India and the USA. As an integral part of the international Glatt Group, Glatt Ingenieurtechnik can draw on a global network of some 3,000 employees. Numerous agencies exist worldwide as contacts for the full range of goods and services. For more information, please visit: 

phone +44 -1455 285-858
email Glatt Protech Ltd. Swannington Road Cottage Lane Ind. Estate Broughton Astley Leicester LE9 6TU United Kingdom
Print this page
Send to a friend
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Clinical Research in Spain


This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement